[Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].
The nucleotide sequences coding the CA-SP1 Pr55(gag) in 61 samples of HIV-1 subtype A variant IDU-A isolated in Russia were analyzed for bevirimat resistance mutations (CA-H226V, CA-L231F, CA-231M, SP1-A1V, SP1-A3T, SP1-A3V) and for polymorphisms in the GAG CA-SP1 cleavage site. None of the six bevirimat resistance mutations was found in the sequences analyzed. There were three polymorphisms CA-G225S, CA-R229K, CA-V2301 and a high variability in the C-terminus of SP1. The substitution SP-T8Q was observed in 98% of cases, which could probably affect the clinical efficacy of bevirimat. Therefore bevirimat can be potentially active in Russian patients infected with IDU-A variant, but strain-specific polymorphisms in combination with other virus genome mutations can influence the efficiency of bevirimat treatment.
Kazennova
E V
EV
Vasil'ev
A V
AV
Bobkova
M R
MR
D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008969:Molecular Sequence Data; D010802:Phylogeny; D011110:Polymorphism, Genetic; D011379:Prognosis; D011498:Protein Precursors / Q000145:classification / Q000235:genetics*; D012426:Russia; D013386:Succinates / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D014315:Triterpenes / Q000494:pharmacology* / Q000627:therapeutic use; D053978:Pentacyclic Triterpenes
D019380:Anti-HIV Agents; D011498:Protein Precursors; D013386:Succinates; D014315:Triterpenes; C059767:p55 gag precursor protein, Human immunodeficiency virus 1; C479935:bevirimat; D053978:Pentacyclic Triterpenes